A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma

Category Systematic review
JournalJournal of Clinical Oncology
Year 2020
This article has no abstract
Epistemonikos ID: 37c94122dd5fcb6315750d80024b53ace776b7b2
First added on: Feb 13, 2025